We would like to thank Wilbrink *et al*.[1](#jdi12858-bib-0001){ref-type="ref"} for their interest and comments on our recent article regarding the glycated hemoglobin (HbA1c)‐lowering effect of glucagon‐like peptide‐1 receptor agonist liraglutide with basal insulin among Japanese individuals with type 2 diabetes.

We have reported that the HbA1c‐lowering effects of liraglutide/basal insulin combination rely on remaining β‐cell function, and that the cut‐off value of the C‐peptide immunoreactivity index, a β‐cell function‐related index frequently used in Japanese clinical settings, is 1.103 for the achievement of HbA1c \< 7.0% at 54 weeks after initiating the liraglutide/basal insulin combination[2](#jdi12858-bib-0002){ref-type="ref"}. In our study, we found that changes in HbA1c were not affected by type 2 diabetes duration, unlike the Wilbrink *et al*. study (Figure [1](#jdi12858-fig-0001){ref-type="fig"}b). This discrepancy might be due to several reasons. First, we studied patients receiving liraglutide/basal insulin combination in replacement of multiple daily injection insulin therapy or basal insulin‐supported oral therapy, whereas Wilbrink *et al*. studied those receiving liraglutide in replacement of insulin therapy. We previously showed that discontinuation of liraglutide as a result of hyperglycemia after switching from insulin is affected by remaining β‐cell function and type 2 diabetes duration[3](#jdi12858-bib-0003){ref-type="ref"}. In addition, we also reported that the HbA1c‐lowering effects of liraglutide monotherapy and sulfonylurea combination rely on remaining β‐cell function and type 2 diabetes duration (Figure [1](#jdi12858-fig-0001){ref-type="fig"}a) in a study in which 74% of the study patients had been taking insulin before initiating liraglutide[4](#jdi12858-bib-0004){ref-type="ref"}. Importantly, the C‐peptide immunoreactivity index cut‐off value for HbA1c \< 7.0% achievement by liraglutide monotherapy and sulfonylurea combination was higher than that of liraglutide/basal combination (1.86 and 1.10, respectively)[2](#jdi12858-bib-0002){ref-type="ref"}, [4](#jdi12858-bib-0004){ref-type="ref"}. It is widely accepted that β‐cell function progressively declines over time in type 2 diabetes patients, making it difficult to obtain appropriate glycemic control without insulin use[5](#jdi12858-bib-0005){ref-type="ref"}, [6](#jdi12858-bib-0006){ref-type="ref"}. It is possible that basal insulin co‐administration compensated for the decline in β‐cell function associated with longer type 2 diabetes duration in our study[2](#jdi12858-bib-0002){ref-type="ref"}. Indeed, it was shown that the addition of basal insulin significantly improved HbA1c in individuals inadequately controlled by liraglutide[7](#jdi12858-bib-0007){ref-type="ref"}. Second, the discrepancy between our study and the Wilbrink *et al*. study might be due to ethnic difference in type 2 diabetes pathophysiology. Type 2 diabetes in East Asian patients is characterized primarily by non‐obesity and β‐cell dysfunction, unlike type 2 diabetes in Caucasian patients, which is characterized by obesity and insulin resistance[8](#jdi12858-bib-0008){ref-type="ref"}. As impaired β‐cell function is observed even in the early stage of type 2 diabetes in East Asian patients, type 2 diabetes duration might have less significance in predicting the HbA1c‐lowering effects of liraglutide. Third, the discrepancy might be due to limited sample size (the Usui study on liraglutide/basal insulin, *n* = 38; the Usui study on liraglutide monotherapy or sulfonylurea combination, *n* = 88; and the Wilbrink *et al*. study, *n* = 69). Dependence of HbA1c‐lowering effects of liraglutide/basal insulin combination on type 2 diabetes duration awaits further investigation by studies with larger sample sizes. Nevertheless, it is conceivable that liraglutide exerts greater HbA1c‐lowering effects in the early stage of type 2 diabetes when ample β‐cell function remains, and that addition of basal insulin or other antidiabetic drugs is required when β‐cell function becomes substantially reduced.

![Changes of glycated hemoglobin (HbA1c) in Japanese patients with type 2 diabetes receiving (a) liraglutide monotherapy or sulfonylureas (SU) combination and (b) liraglutide/basal insulin combination. The patients were subdivided into two groups by medians of type 2 diabetes duration: (a) 10 years and (b) 16 years. Blue, those with type 2 diabetes duration below the median: (a) *n* = 37 and (b) *n* = 18); and red, those with type 2 diabetes duration with the median or above: (a) *n* = 51 and (b) *n* = 19). Time‐course curves were analyzed by mixed‐effects models including group, time, and the interaction of group and time, and the *P*‐values are shown. ^\#^ *P* \< 0.05 (*vs* patients with the median or above) by the Mann--Whitney *U*‐test. The statistical analysis was carried out using SPSS Statistics 24 software (IBM Corp., Armonk, New York, USA). Each value represents the mean ± standard error of the mean.](JDI-9-981-g001){#jdi12858-fig-0001}
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